Cognito’s OVERTURE trial demonstrated significant ‘time saved’ in functional and cognitive decline at both six and 18 months.

A clinical trial of the drug Trontinemab will aim to delay or prevent the symptoms of Alzheimer's disease, Swiss drugmaker Roche says.

The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects ...